Literature DB >> 31850862

Blood transfusions and adverse acute events: a retrospective study from 214 transfusion-dependent pediatric patients comparing transfused blood components by apheresis or by whole blood.

Maria Rosaria De Pascale1, Angela Belsito2, Linda Sommese3, Simona Signoriello4, Antonio Sorriento5, Maria Vasco6, Concetta Schiano7, Carmela Fiorito6, Giuseppe Durevole6, Marina Casale8, Silverio Perrotta8, Fiorina Casale8, Roberto Alfano9, Giuditta Benincasa7, Giovanni Francesco Nicoletti10, Claudio Napoli7.   

Abstract

INTRODUCTION: Blood transfusion is a lifesaving procedure for patients affected by hematological diseases or hemorrhage risk. AIM: This retrospective study was aimed to evaluate clinical safety of pediatric transfusions by comparing the frequency of adverse events caused by apheretic blood components vs whole blood.
METHODS: From 2011 to 2015, 214 patients (blood malignancy patients, n = 144 and thalassemic patients, n = 70) received 12 531 units of blood components. The adverse acute reactions occurred during patient hospitalization were reported to the Hemovigilance system and assessed by fitting a logistic mixed-effect model.
RESULTS: A total of 33 (0.3%) adverse acute events occurred. Odds ratio (OR) of adverse events from apheresis vs whole blood transfusion adjusted by patient classification was not statistically significant (OR [95% CI], 0.75 [0.23-2.47]).
CONCLUSION: Our findings showed no significant differences in the prevalence of adverse acute events between blood component collected by apheresis vs whole blood in our study center.

Entities:  

Mesh:

Year:  2019        PMID: 31850862     DOI: 10.4415/ANN_19_04_08

Source DB:  PubMed          Journal:  Ann Ist Super Sanita        ISSN: 0021-2571            Impact factor:   1.663


  1 in total

1.  Analysis of Adverse Reactions of Blood Transfusion and Discussion of Influencing Factors in Linyi Area from 2013 To 2020.

Authors:  Xiuping Zhang; Yanli Zhang; Cao Qi; Chunling Ma
Journal:  Iran J Public Health       Date:  2021-07       Impact factor: 1.429

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.